Quirt 1996.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 56, lung, gynecological, hematological malignancies, other cancer; concomitant treatment: chemotherapy
Interventions	drug = Epoetin alpha dose = 150 IU/kg sc TIW hb‐target = 12.5‐14 g/dL planned ESA duration = 16 weeks
Outcomes	Primary: transfusion; secondary: QoL, costs from societal perspective, tumor response
Notes	study number = 80214
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	no description
Allocation concealment?	Unclear risk	no description